Strategy Target Drug Immune checkpoint inhibitor Status Clincal trial
Block the recruitment CXCR1 LY2510924 Durvalumab Terminated NCT02737072
CXCR1/CXCR2 SX-682 Nivolumab Recruiting NCT04477343
Tislelizumab Recruiting NCT05604560
CXCR4 BL-8040 Pembrolizumab Active, not Recruiting NCT02907099
Completed NCT02826486
Cemiplimab Recruiting NCT04543071
Atezolizumab Recruiting NCT03193190
AMD3100 Cemiplimab Completed NCT04177810
CXCR2/CXCR5 BMS-813160 Nivolumab Completed NCT03184870
Recruiting NCT03767582
CXCL12 NOX-A12 Pembrolizumab Not yet Recruiting NCT04901741
Completed NCT03168139
IL-8 BMS-986253 Nivolumab Recruiting NCT02451982
IL-6 Tocilizumab Ipilimumab, Nivolumab Terminated NCT04258150
Block polarization TGF-β LY2157299 Durvalumab Completed NCT02734160
AGEN1423 Balstilimab Not yet recruiting NCT05632328
TGFβ peptide vaccine Ipilimumab Recruiting NCT05721846